Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Race Oncology Ltd. ( (AU:RAC) ).
Race Oncology has disclosed a change in the holdings of director Daniel Tillett, who exercised 400,000 options at an exercise price of $1.25 each, investing $500,000 to convert them into fully paid ordinary shares. Following this transaction, Tillett’s direct interest increased to 18,472,378 ordinary shares, while his remaining options at the $1.25 strike decreased to 1,748,342, with no trades occurring during a closed period, signalling continued director alignment with shareholders through increased equity exposure.
The most recent analyst rating on (AU:RAC) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Race Oncology Ltd. stock, see the AU:RAC Stock Forecast page.
More about Race Oncology Ltd.
Race Oncology Limited (referred to in the filing as Racura Oncology Limited) operates in the biotechnology/pharmaceutical sector, focusing on oncology drug development. The company is listed on the ASX and raises capital in part through the issuance of options and ordinary shares to directors and other stakeholders.
Average Trading Volume: 245,179
Technical Sentiment Signal: Buy
Current Market Cap: A$551.7M
For detailed information about RAC stock, go to TipRanks’ Stock Analysis page.